As filed with the Securities and Exchange Commission on June 10, 2021
Registration
No. 333-
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
AVEO Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
Delaware
|
|
04-3581650
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
30 Winter Street
Boston, Massachusetts
|
|
02108
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
AVEO Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended
AVEO Pharmaceuticals, Inc. Amended and Restated 2010 Employee Stock Purchase Plan
(Full Title of the Plan)
Erick Lucera
Chief
Financial Officer
AVEO Pharmaceuticals, Inc.
30 Winter Street
Boston,
Massachusetts 02108
(Name and Address of Agent For Service)
(857) 400-0101
(Telephone Number, Including Area Code, of Agent For Service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☒
|
|
Smaller reporting company
|
|
☒
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐